Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer

By Kroep J.   Smit E.   Giaccone G.   Born K.   Beijnen J.   Groeningen C.   Vijgh W.   Postmus P.   Pinedo H.   Peters G.  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 4, 2006-10 ,pp. : 509-516

Springer Publishing Company

Access to resources Recommend Favorite

Efficient downregulation of ErbB-2 induces TACC1 upregulation in breast cancer cell lines

By Xiang Jinyu   Qiu Wensheng   Wang Xingang   Zhou Fang   Wang Zhen   Liu Shihai   Yue Lu  

Oncology Reports, Vol. 29, Iss. 4, 2013-04 ,pp. : 1517-1523

Spandidos Publications

Access to resources Recommend Favorite

A study on the expression of erbB4/HER4 in non-small cell lung cancer

By Deng Zaichun  

The Chinese-German Journal of Clinical Oncology, Vol. 7, Iss. 2, 2008-02 ,pp. : 75-77

Springer Publishing Company

Access to resources Recommend Favorite

Autocrine Signalling Through erbB Receptors Promotes Constitutive Activation of Protein Kinase B/Akt in Breast Cancer Cell Lines

By Nicholson K.M.  

Breast Cancer Research and Treatment, Vol. 81, Iss. 2, 2003-09 ,pp. : 117-128

Springer Publishing Company

Access to resources Recommend Favorite

Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples

By Konecny G.  

Breast Cancer Research and Treatment, Vol. 67, Iss. 3, 2001-06 ,pp. : 223-233

Springer Publishing Company

Access to resources Recommend Favorite